Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world add-on Enox study in pediatric Lennox-Gastaut syndrome
ChiCTR2400086241Phase 4Not yet recruiting
- Sponsor
- Wuhan Women and Children's Health Care Center
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enoxaparin in Lennox-Gastaut syndrome (LGS), sponsored by Wuhan Women and Children's Health Care Center. Primary endpoint: Incidence of adverse events and adverse reactions of central nervous system somnolence. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on ChiCTR2400086241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086241.